Alvaro Gomez Gonzalez

About me
Publications
Public outreach and news

Research

The general aim of my doctoral project is to optimise the use of current therapeutic strategies in patients with systemic lupus erythematosus. My project has two main branches: (i) to identify demographical, clinical and immunological factors that influence the efficacy of current therapies, with special focus on biologics targeting B cells
(ii) to determine the impact of pharmacological and non-pharmacological factors on patient’s health-related quality of life. Furthermore, we study the performance of different composite outcomes as well as patient reported outcomes in clinical trial settings.

Articles

Journal article: RHEUMATOLOGY. 2024;63(2):338-348

Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.

Gomez A; Jägerback S; Sjöwall C; Parodis I
Journal article: RHEUMATOLOGY. 2024;:keae023

Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab.

Jägerback S; Gomez A; Parodis I
Article: RHEUMATOLOGY. 2023;62(12):3916-3923

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State.

Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: FRONTIERS IN MEDICINE. 2023;10:1247354

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus.

Borg A; Lindblom J; Gomez A; Soltani A; Enman Y; Heintz E; Regardt M; Grannas D; Emamikia S; Parodis I
Article: RHEUMATOLOGY. 2022;61(12):4752-4762

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.

Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(22):13941

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.

Parodis I; Gomez A; Lindblom J; Chow JW; Sjöwall C; Sciascia S; Gatto M
Article: AUTOIMMUNITY REVIEWS. 2022;21(11):103188

Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature.

Gomez A; Parodis I
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:796508

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab.

Parodis I; Gomez A; Chow JW; Borg A; Lindblom J; Gatto M
Article: FRONTIERS IN MEDICINE. 2022;9:1092325

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus.

Lindblom J; Zetterberg S; Emamikia S; Borg A; von Perner G; Enman Y; Heintz E; Regardt M; Grannas D; Gomez A; Parodis I
Article: FRONTIERS IN MEDICINE. 2022;9:852162

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.

Parodis I; Gomez A; Lindblom J; Chow JW; Doria A; Gatto M
Article: RHEUMATOLOGY. 2021;60(10):4703-4716

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus.

Lindblom J; Gomez A; Borg A; Emamikia S; Ladakis D; Matilla J; Pehr M; Cobar F; Enman Y; Heintz E; Regardt M; Parodis I
Article: RHEUMATOLOGY. 2021;60(9):4205-4217

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE.

Borg A; Gomez A; Cederlund A; Cobar F; Qiu V; Lindblom J; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: RHEUMATOLOGY. 2021;60(3):1260-1272

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus.

Gomez A; Hani Butrus F; Johansson P; Åkerström E; Soukka S; Emamikia S; Enman Y; Pettersson S; Parodis I
Article: FRONTIERS IN MEDICINE. 2021;8:651249

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus.

Gomez A; Qiu V; Cederlund A; Borg A; Lindblom J; Emamikia S; Enman Y; Lampa J; Parodis I
Article: RHEUMATOLOGY. 2020;59(11):3424-3434

Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis.

Parodis I; Adamichou C; Aydin S; Gomez A; Demoulin N; Weinmann-Menke J; Houssiau FA; Tamirou F
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(6):E1813-1813

Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus.

Gomez A; Soukka S; Johansson P; Åkerström E; Emamikia S; Enman Y; Chatzidionysiou K; Parodis I
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;21(10):E3463-3463

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus.

Parodis I; Åkerström E; Sjöwall C; Sohrabian A; Jönsen A; Gomez A; Frodlund M; Zickert A; Bengtsson AA; Rönnelid J; Gunnarsson I
Article: RHEUMATOLOGY. 2019;58(12):2170-2176

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.

Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Article: LANCET RHEUMATOLOGY. 2019;1(3):E163-E173

Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials.

Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(2):157-168

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.

Parodis I; Emamikia S; Gomez A; Gunnarsson I; van Vollenhoven RF; Chatzidionysiou K
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2018;18(8):911-920

Smoking reduces the efficacy of belimumab in mucocutaneous lupus.

Parodis I; Gomez A; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I
Journal article: PLOS ONE. 2017;12(9):e0184189

Aged blood factors decrease cellular responses associated with delayed gingival wound repair.

Saldías MP; Fernández C; Morgan A; Díaz C; Morales D; Jaña F; Gómez A; Silva A; Briceño F; Oyarzún A; Maldonado F; Cerda O; Smith PC; Cáceres M
Show more

All other publications

Review: RMD OPEN. 2023;9(3):e003297

Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.

Parodis I; Gomez A; Tsoi A; Chow JW; Pezzella D; Girard C; Stamm TA; Boström C
Review: PATIENT RELATED OUTCOME MEASURES. 2023;14:1-13

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence.

Gomez A; Enman Y; Parodis I
Letter: AUTOIMMUNITY REVIEWS. 2019;18(10):102372

Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus.

Hernández-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2019;78(7):1006-1007

Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.

Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:781-782

ANTIMALARIAL AGENTS IMPROVE PHYSICAL FUNCTIONING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Parodis I; Soukka S; Gomez A; Enman Y; Johansson P; Emamikia S; Chatzidionysiou K
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:777-778

ANTIMALARIAL AGENTS DIMINISH WHILE METHOTREXATE, AZATHIOPRINE AND MYCOPHENOLIC ACID INCREASE BAFF LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS

Hernandez-Breijo B; Gomez A; Soukka S; Johansson P; Parodis I
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2019;78:761

PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K

Research

Articles

All other publications

News from KI

Events from KI